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Abstract The lymphatic vascular system, the body’s sec-
ond vascular system present in vertebrates, has emerged in
recent years as a crucial player in normal and pathological
processes. It participates in the maintenance of normal
tissue Xuid balance, the immune functions of cellular and
antigen traYcking and absorption of fatty acids and lipid-
soluble vitamins in the gut. Recent scientiWc discoveries
have highlighted the role of lymphatic system in a number
of pathologic conditions, including lymphedema, inXam-
matory diseases, and tumor metastasis. Development of
genetically modiWed animal models, identiWcation of lym-
phatic endothelial speciWc markers and regulators coupled
with technological advances such as high-resolution imag-
ing and genome-wide approaches have been instrumental in
understanding the major steps controling growth and
remodeling of lymphatic vessels. This review highlights the
recent insights and developments in the Weld of lymphatic
vascular biology.
Keywords Lymphangiogenesis · Lymphedema · 
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Introduction
The complexity of the circulatory networks of animals
tends to increase as species increase in size. Apart from the
cardiovascular system, vertebrates also possess a lymphatic
system that consists of the lymphatic vessels and the lym-
phoid organs such as lymph nodes, mucosal-associated
lymphoid tissue (MALT) (tonsils, Peyer’s patches, and
lymphoid tissues associated to the bronchial and nasal sys-
tems), spleen, and thymus. Blood and lymphatic vessels
comprise two interdependent vascular networks in most tis-
sues; however, their organization and function are distinct.
The cardiovascular system forms a continuous loop around
which the heart pumps blood, whereas the lymphatic sys-
tem comprises a one-way, open-ended transit network with-
out a central driving force. Blood vessels deliver blood
cells, nutrients, hormones, and oxygen to tissues, whereas
lymphatic vasculature removes macromolecules, microbes,
and other substances from interstitial space.
The lymphatic system comprises a network of blind-
ended lymphatic capillaries (also called initial lymphatic
vessels) that collect the excess extravasated tissue Xuid that
has originated as capillary inWltration from the blood serum
(Fig. 1). After being collected by the lymphatic capillaries,
the lymph is transported through a system of lymphatic ves-
sels of progressively larger size, to pre-collector lymphatic
vessels (Sacchi et al. 1997) then larger collecting lymphatic
vessels, which converge into lymphatic trunks, and the
lymph is Wnally returned to the venous circulation via a
connection with subclavian veins (Casley-Smith 1980;
Moore 1985). Thus the main function of the lymphatic sys-
tem is to maintain normal tissue Xuid balance by restoring
interstitial Xuid to the cardiovascular system. In addition, in
the digestive tract, lacteal lymphatic vessels inside the
intestinal villi absorb and transport fat-soluble vitamins
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the form of lipid particles called chylomicrons. Further-
more, the lymphatic system is an important part of immune
surveillance by carrying antigens and antigen presenting
cells from the interstitium to be displayed for B and T cells
in the lymph nodes. In addition to these physiological tasks
the lymphatic system plays a major role in a number of
pathologic conditions, including lymphedema, inXamma-
tory diseases, and tumor metastasis.
Present in the skin and in most internal organs, with the
exception of avascular structures such as epidermis, hair,
nails, cartilage, and cornea, and some vascularised organs
such as the brain, bone marrow, and retina, the lymphatic
vasculature is composed of vessels with distinct morpho-
logical features (Fig. 1). Similar to blood capillaries, lym-
phatic capillaries consist of a single layer of thin-walled,
non-fenestrated lymphatic endothelial cells (LECs), but
they diVer in that they are not ensheathed by pericytes or
smooth muscle cells (SMCs), and have an absent or poorly
developed basement membrane. In addition, they lack tight
junctions and adherens junctions, which allow easy access
for Xuid, macromolecules, and cells into the vessel lumen
(Leak 1976). Endothelial cells of lymphatic capillaries are
oak leaf shaped and are interconnected by specialized
discontinuous button-like junctions, whereas collecting
lymphatic vessels downstream have continuous zipper-like
junctions found also in blood vessels (Baluk et al. 2007).
Overlapping endothelial cell–cell contacts (also called pri-
mary valves) in initial lymphatic vessels prevent Xuid
escaping back into the interstitial space (Schmid-Schönbein
2003; Trzewik et al. 2001). Lymphatic capillary endothelial
cells are closely linked to the surrounding extracellular
matrix by elastic Wbers known as anchoring Wlaments (Gerli
et al. 1991; Leak and Burke 1968), which prevent vessel
collapse in conditions of high interstitial pressure, indeed in
this condition the junctions of the initial lymphatics open
and the anchoring Wlaments stretch, allowing Xuid to move
into the vessel. Anchoring Wlaments are made of Wbrillin
(Gerli et al. 2000; Solito et al. 1997), a large glycoprotein
that contains an Arg–Gly–Asp (RGD) motif capable of
binding v3 integrins, which are transmembrane glyco-
proteins that cluster at focal adhesion plaques. Pre-collector
lymphatic vessels are characterized by the alternation of
areas with the same structural simplicity as initial lym-
phatic capillaries and areas with a well-developed muscular
coat, but the ultrastructural features of these diVerent por-
tions do not diVer, and anchoring Wlaments are present in
both (Scavelli et al. 2004). The pre-collecting lymphatic
vessels merge into collecting lymphatic vessels, and the two
types of vessels have a basement membrane, and are sur-
rounded by SMCs with intrinsic contractile activity to pro-
mote lymph Xow. The latter is also due to the contraction of
surrounding skeletal muscles, as well as arterial pulsations.
Like veins, the larger lymphatic vessels contain one-way
intraluminal valves that aid in lymph propulsion by prevent-
ing backXow (Leak and Burke 1966; von der Weid and
Zawieja 2004). Compared to blood vessels, the lymphatic
vasculature is a low Xow and low pressure system.
Development of lymphatic vasculature
Embryonic development concepts
The Wrst description of the lymphatic system dates back to
the seventeenth century, when Gasparo Aselli identiWed
lymphatic vessels as ‘‘milky veins’’ in the mesentery of a
‘‘well-fed’’ dog (Asellius 1627). However, the embryonic
origin of lymphatic vessels remained unclear for a long
time until F. Sabin (1902, 1909) and F. Lewis (1905) postu-
lated, at the beginning of the twentieth century, that LECs
are derived from the venous endothelium. This “centrifu-
gal” theory proposes that endothelial cells bud oV from the
veins during early embryonic development and form primi-
tive lymph sacs in the jugular region (reviewed by Oliver
Fig. 1 Organization of lymphatic vascular system. The lymph is col-
lected by a network of blind-ended lymphatic capillaries and is trans-
ported by pre-collector lymphatic vessels and collecting lymphatic
vessels, which are emptied into veins in the jugular region. Lymphatic
capillaries consist of thin-walled lymphatic endothelial cells with over-
lapping junctions which look like valves. Anchoring Wlaments, con-
taining Wbrillin, connect lymphatic capillaries to the extracellular
matrix and prevent vessel collapse during increased interstitial pres-
sure. The pre-collector and collecting lymphatic vessels have a base-
ment membrane, are surrounded by smooth muscle cells (red) and
contain intraluminal valves that prevent lymph blackXow123
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gally sprout towards the periphery, forming capillaries that
surround tissues and organs. An alternative, “centripetal”
theory, suggests that LECs are derived from mesenchymal
progenitor cells, which, nowadays, are called lymphangio-
blasts (Huntington and Mc Clure 1910). Several recent
studies in genetically engineered mouse models (Srinivasan
et al. 2007; Wigle et al. 2002; Wigle and Oliver 1999) and
in vivo imaging of developing lymphatic vasculature in
zebraWsh (Yaniv et al. 2006) provide strong support for the
venous origin of lymphatic vessels. Lineage tracing experi-
ments demonstrate that LECs originating in embryonic
veins are the main source for the developing lymphatic vas-
culature; they have also identiWed some of the molecular
determinants that control the step-wise process of lym-
phatic competence, commitment, diVerentiation and matu-
ration (reviewed in Adams and Alitalo 2007; Karpanen and
Alitalo 2008; Oliver 2004).
An intermediate position favouring a dual origin from
embryonic veins and mesenchymal lymphangioblasts is also
proposed. Grafting experiments in avian embryos suggest
that while the deep parts of the lymph sacs are derived from
adjacent veins, the superWcial parts of the jugular lymph sacs
and the dermal lymphatics arise from local lymphangio-
blasts (Wilting et al. 2006). In Xenopus tadpoles, PROX1-
positive mesodermal precursor cells, lymphangioblasts,
which share a common origin with vascular progenitor cells,
contribute to lymphatic vessel formation (Ny et al. 2005). In
murine embryos, scattered mesenchymal cells, which coex-
press leukocyte (CD45) and lymphatic endothelial markers
(LYVE-1, PROX1), were detected in the regions of new
lymphatic vessel growth; and it was suggested that the triple
positive cells (LYVE-1+, PROX1+, F4/80+) with characteris-
tics of LECs and macrophages may integrate into lymphatic
vessels (Buttler et al. 2006, 2008a). The functional role of
such cells remains unclear, as formation of lymph sacs is not
aVected in Runx1¡/¡ mice, which have defective hematopoi-
esis, and lineage tracing studies failed to demonstrate contri-
bution of hematopoietic cells to lymphatic endothelium up
to the embryonic day E16.5 (Buttler et al. 2008b; Srinivasan
et al. 2007). A possibility remains that hematopoietic cells
contribute to developmental lymphangiogenesis in a non-
cell autonomous manner, as described previously for angio-
genesis (Takakura et al. 2000).
In adults, similar to blood vessels, the lymphatic vascu-
lature remains in quiescent state with the exception of situa-
tions of tissue and organ regeneration, wound healing,
tumor growth, and in inXammation. New lymphatic vessels
primarily grow by sprouting from existing ones; in addi-
tion, the hematopoietic cell-derived circulating endothelial
progenitors and transdiVerentiating macrophages are puta-
tive sources of LECs during pathological lymphangiogene-
sis, such as during chronic renal transplant rejection or
corneal lymphangiogenesis (Maruyama et al. 2005; Religa
et al. 2005; Schledzewski et al. 2006). However, bone mar-
row-derived progenitor cells did not incorporate signiW-
cantly into the endothelium of newly formed lymphatic
vessels in mouse tumor xenografts (He et al. 2004), and
more generally, a growing body of evidence suggest that
circulating bone marrow-derived progenitor cells may pro-
mote growth of vessels mainly by acting as supporting cells
(Grunewald et al. 2006; Purhonen et al. 2008).
Mechanisms of lymphatic vascular development
Lymphatic endothelial cell fate commitment
During embryogenesis, the development of lymphatic ves-
sels starts after the establishment of a functional blood vas-
culature. LYVE-1, lymphatic endothelial hyaluronan
receptor-1, is the Wrst indicator of lymphatic endothelial
commitment, and is expressed in mice from embryonic day
E9 in a polarized manner in the LECs diVerentiating in
venous endothelium (Oliver 2004). It has been proposed
that LYVE-1 expression in the embryonic cardinal veins
signiWes competence of the venous endothelium to receive
an inductive signal that results in lymphatic endothelial cell
fate speciWcation (Wigle et al. 2002). In adults, LYVE-1 is
downregulated in the collecting lymphatic vessels but
remains high in lymphatic capillaries (Makinen et al. 2005).
In addition to lymphatic endothelium, LYVE-1 is also
expressed on blood vessels of the yolk sac and intra-embry-
onic arterial and venous endothelium at early embryonic
stages, on endothelial cells of the lung and endocardium
throughout embryogenesis, as well as in liver sinusoids
(Gordon et al. 2008). LYVE-1 is thought to participate in
hyaluronan transport and leukocyte migration across the
lymphatic vessel wall (Jackson 2004). Lyve1¡/- mice do not
display lymphatic vascular defects, suggesting the exis-
tence of compensatory mechanisms (Gale et al. 2007).
The transcription factor prospero-related homeobox 1,
PROX1, controls the initial steps of lymphangiogenesis and
is the most speciWc lineage marker for lymphatic endothe-
lium (reviewed in Oliver and Detmar 2002). Targeted inac-
tivation of Prox1 in mice leads to a complete absence of
lymphatic vessels, while blood vasculature development
proceeds normally (Wigle et al. 2002; Wigle and Oliver
1999). Around E9.5 of mouse development, polarized
expression of PROX1 is observed on one side of the ante-
rior cardinal veins and soon thereafter these cells start bud-
ding and migrating in a polarized manner, eventually
forming lymph sacs. PROX1 acts as a master regulator of
lymphatic endothelial diVerentiation, as in the absence of
PROX1 endothelial cells continue to express blood vascu-
lar endothelial cell (BECs) markers, while the ectopic
expression of PROX1 in human BECs induces expression123
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vascular-speciWc transcripts (Hong et al. 2002; Petrova
et al. 2002; Wigle et al. 2002). At present, the signals that
induce PROX1 expression in a restricted subpopulation of
endothelial cells are not well understood. Interleukin (IL)-3
and IL-7 have been shown to induce PROX1 expression in
human cultured BECs, but whether they provide signals for
lymphatic diVerentiation in vivo has not yet been addressed
(Al-Rawi et al. 2005; Groger et al. 2004). In addition, direct
PROX1 target genes that mediate its function during the
process of lymphangiogenesis are not known. In cultured
endothelial cells, PROX1 has been shown to induce the
expression of important genes regulating lymphatic devel-
opment, such as vascular endothelial growth factor recep-
tor-3 (VEGFR-3) (Petrova et al. 2002; Saharinen and
Petrova 2004; Wigle et al. 2002) and integrin-9 (Mishima
et al. 2007) thereby promoting the migration of LECs
towards the VEGFR-3 ligand, VEGF-C, and regulating the
endothelial sheet formation (Mishima et al. 2007). PROX1
also regulates the expression of Wbroblast growth factor
receptor-3 (FGFR-3) in vitro (Shin et al. 2006), however,
the role of FGFR-3 in lymphatic vascular development in
vivo remains to be investigated.
Lymphatic sprouting
Endothelial receptor tyrosine kinase VEGFR-3 and its
ligand VEGF-C are required for the survival, maintenance,
and migration of lymphatic vessels during embryonic
development (reviewed by Karpanen and Alitalo 2008;
Tammela et al. 2005a) and a 2 week postnatal period, after
which lymphatic vessels become independent of VEGFR-3
(Karpanen et al. 2006b). During early development,
VEGFR-3 is expressed in all endothelial cells and is impor-
tant for blood vascular remodeling (Dumont et al. 1998;
Hamada et al. 2000), indeed Vegfr3-deWcient mice die at
E9.5 owing to cardiovascular failure. At the onset of lym-
phangiogenesis, VEGFR-3 expression becomes restricted
to newly forming LECs (Dumont et al. 1998). However,
VEGFR-3 is upregulated in the blood microvasculature of
tumors (Valtola et al. 1999) and wounds (Paavonen et al.
2000). Moreover, VEGFR-3 is highly expressed in angio-
genic sprouts and blocking of VEGFR-3 signaling results in
decreased sprouting, vascular density, vessel branching and
endothelial cell proliferation (Tammela et al. 2008). The
two known ligands of VEGFR-3, VEGF-C, and VEGF-D,
can induce lymphangiogenesis in vivo and stimulate proli-
feration, survival, and migration of LECs in vitro (Jeltsch
et al. 1997; Mäkinen et al. 2001; Veikkola et al. 2001).
VEGF-C is expressed by mesenchymal cells surrounding
the cardinal veins, and is essential for the initial sprouting
and directed migration as well as for the subsequent sur-
vival of LECs. Consequently, in the absence of Vegfc,
PROX1+ LECs arise normally in the embryonic veins, but
are unable to sprout and migrate from their original loca-
tion, and Vegfc deWcient mice do not develop a lymphatic
vasculature (Karkkainen et al. 2004). VEGF-D is dispens-
able for lymphatic vascular development, and Vegfd¡/-
embryos display only mild hypoplasia of the pulmonary
lymphatic vasculature, although exogenous VEGF-D pro-
tein rescues the impaired vessel sprouting in Vegfc¡/-
embryos (Baldwin et al. 2005; Karkkainen et al. 2004).
After proteolytic cleavage, fully processed, mature
forms of VEGF-C and VEGF-D serve as also ligands for
the major regulator of angiogenesis, VEGFR-2 (Achen
et al. 1998; Joukov et al. 1997). It has recently been sug-
gested that cooperative signaling between VEGFR-2 and
VEGFR-3 is required for LECs migration and proliferation,
whereas VEGFR-3 is redundant with VEGFR-2 for the
organization of LECs into functional capillaries (Goldman
et al. 2007). However, when activated by overexpression of
VEGF or the related VEGFR-2-speciWc ligand VEGF-E,
VEGFR-2 signals only promote lymphatic vessel enlarge-
ment and are not involved in vessel sprouting to generate
new lymphatic vessels in vivo (Wirzenius et al. 2007).
Moreover, a mutant form of VEGF-C unable to stimulate
VEGFR-2 is suYcient for stimulating lymphangiogenesis
(Joukov et al. 1998; Veikkola et al. 2001).
The importance of VEGF-C/VEGFR-3 pathway for lym-
phatic vascular development has been recently highlighted
by studies in zebraWsh, which resolved a long standing con-
troversy about the presence of lymphatic vessels in teleost
Wshes (Küchler et al. 2006; Vogel and Claviez 1981; Yaniv
et al. 2006). ZebraWsh lymphatic vessels express high levels
of Prox1, Nrp2 (neuropilin-2), Vegfr3, and Angpt2 (angio-
poietin-2) and, knock-down of Prox1 and Vegfc or inhibi-
tion of VEGFR-3 signaling by expression of VEGF-C trap
VEGFR-3-Ig fusion protein prevents the formation of lym-
phatic vasculature (Küchler et al. 2006; Yaniv et al. 2006).
Use of zebraWsh or Xenopus embryos as small vertebrate
models oVers unparalled opportunities for identiWcation of
novel regulators of lymphatic vascular development and
detailed analysis using in vivo imaging approaches (Ny
et al. 2005; Yaniv et al. 2006).
In addition to VEGF-C and VEGF-D, extracellular
matrix proteins, collagen, and Wbronectin, enhance tyrosine
phosphorylation of VEGFR-3 through activation of integrin
1, which interacts directly with VEGFR-3 (Wang et al.
2001). As mice deWcient in both Vegfc and Vegfd, unlike
Vegfr3 null mice, have normal blood vascular development
(Haiko et al. 2008), it is likely that other VEGFR-3 ligands,
such as integrins, contribute to VEGFR-3 signaling in
blood vascular endothelium. Additional VEGF-C signal
transduction pathways were also described, such as inter-
action of VEGF-C with neuropilin-2 (NP2) and integrin 9.
Indeed, NP2 is cointernalized along with VEGFR-3 in the123
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ulation with VEGF-C or VEGF-D, suggesting that NP2
modulates VEGFR-3 signaling (Karpanen et al. 2006a).
The formation of small lymphatic vessels and capillaries is
abnormal in Nrp2 knockout mice, these vessels are absent
or severely reduced until postnatal stages, whereas larger
lymphatic vessels develop normally (Yuan et al. 2002). It
may be signiWcant that integrin 91 binds VEGF-C and
VEGF-D, and endothelial adhesion to and migration on the
lymphangiogenic vascular endothelial growth factors
(VEGF-C and -D) are 91-dependent (Vlahakis et al.
2005). Mice deWcient in the integrin 9 chain die of chylo-
thorax during the early postnatal period, suggesting an
underlying function for integrin 91 in the normal devel-
opment of the lymphatic system, including the thoracic
duct (Huang et al. 2000).
Several other growth factors with lymphangiogenic func-
tion have been proposed, including Wbroblast growth factor-2
(FGF-2), platelet-derived growth factors (PDGFs), insulin-
like growth factors (IGFs), hepatocyte growth factor (HGF)
and growth hormone (GH) (Banziger-Tobler et al. 2008;
Björndahl et al. 2005; Cao et al. 2004, 2006; Chang et al.
2004; Kajiya et al. 2005; Kubo et al. 2002; Saito et al. 2006;
Shin et al. 2006). While all of them are capable of stimulat-
ing the proliferation of lymphatic endothelial cells in vitro or
sometimes upon overexpression in vivo, their deWnitive role
in developmental or pathological lymphangiogenesis via
loss-of-function analysis remains to be established. Indirect
lymphangiogenic eVect in vivo, for example through an
increased recruitment of VEGF-C/D expressing inXamma-
tory cells, is a plausible alternative for FGF-2 and HGF
action (Cao et al. 2006; Chang et al. 2004; Kubo et al. 2002).
Separation of blood and lymphatic vasculature
The primary lymphatic plexus, which begins to form in
mice around E10.5–E11, is composed of capillary-like ves-
sels and is initially connected to the blood vasculature. In
adults, apart the lymphatico-venous communications in the
renal, hepatic, and adrenal veins, and in the lymph nodes,
the main connections of blood and lymphatic vasculature
locate at the junction where thoracic and right lymphatic
ducts empty their contents into the subclavian veins. This
suggests that mechanisms exist for keeping the blood and
lymphatic vascular compartments separate. Tyrosine kinase
Syk and adaptor protein Slp76 are important for this separa-
tion (Abtahian et al. 2003; Sebzda et al. 2006), as deW-
ciency in Syk or Slp76 results in arterio-venous shunting
and mixing of blood and lymphatic endothelial cells, which
ultimately leads to haemorrhaging and perinatal death. The
model proposed is that the exit of progenitors from veins is
defective, and this leads to the formation of lymphovenous
connections. Syk and Slp76 are expressed almost exclu-
sively in hematopoietic cells, suggesting a role for this cell
type in regulating the separation of the blood and lymphatic
vascular networks.
Fasting-induced adipose factor (Fiaf) (or angiopoietin-
like protein 4 (Angptl4)) is another factor involved in the
regulation of lymphatic and blood vessel separation in the
intestine. Mice deWcient in Fiaf developed normally until
birth, but displayed blood-Wlled intestinal lymphatic vessels
post-natally, and decreased Prox1 expression was observed
on the LYVE-1+ vessels in Fiaf¡/¡ mice (Bäckhed et al.
2007). However, the underlying mechanisms, including the
identiWcation of the Fiaf receptor, remain to be investi-
gated. This study suggests that active and organ-speciWc
mechanisms are required after birth to preserve the separa-
tion of the blood and lymphatic vascular systems.
Maturation of the lymphatic vasculature
The primary lymphatic plexus undergoes a further dramatic
change to form a hierarchically organized network of
lymph vessels, composed of capillaries devoid of basement
membrane and pericytes, and collecting lymphatic vessels
containing intraluminal valves, basement membrane, and
covered with SMCs. This complex process of reorganiza-
tion of lymph vessels is referred as “lymphatic vascular
maturation”, during which new capillaries arise by sprout-
ing from the pre-existing vasculature, SMCs on collecting
vessels are recruited and luminal valves are formed. Angio-
poietin-2, EphrinB2, FOXC2, and Podoplanin have been
shown to play important roles at late steps of lymphatic
vascular development.
Angiopoietins and Tie receptors are involved in the
remodeling and stabilization of lymphatic vessels. Three
members of the Angiopoietin family (Ang1, Ang2, and
Ang3/4) are ligands for the Tie1 and/or Tie2 receptor tyro-
sine kinases, which are expressed both in blood vascular and
lymphatic endothelia (Iljin et al. 2002; Morisada et al. 2005;
Tammela et al. 2005b). Ang1 can activate both Tie1 and
Tie2 that appear as preformed heteromeric complexes
between the two receptor molecules (Saharinen et al. 2005).
Overexpression of Ang1 in adult mice stimulates lymphatic
endothelial cell proliferation and promotes vessel enlarge-
ment and generation of new sprouts (Morisada et al. 2005;
Tammela et al. 2005b). Ang2 is required for postnatal blood
vascular remodeling and proper development of the lym-
phatic vasculature. Angpt2-deWcient mice display a disorga-
nization and hyperplasia of the vessels caused by impaired
recruitment of SMCs onto collecting lymphatic vessels and
an irregularly patterned hypoplastic lymphatic capillary net-
work. Interestingly, replacement of Ang2 by Ang1 was suY-
cient to rescue the lymphatic phenotype (Gale et al. 2002).
During vascular development, EphrinB2 plays important
roles in the remodeling of the arterial-venous capillary123
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culature. EphrinB2 is expressed in collecting lymphatic
vessels, whereas its receptor EphB4 is detected both in col-
lecting lymphatic vessels and in lymphatic capillaries. Mice
lacking the PDZ interaction domain of EphrinB2, develop
an apparently normal blood vasculature, but fail to establish
a hierarchically organized lymphatic vessel network con-
sisting of lymphatic capillaries and collecting vessels.
These mutants display defects in the formation of luminal
valves in the collecting vessels, ectopic SMC coverage in
lymphatic capillaries, and persistent expression of LYVE-1
in all lymphatic vessels (Makinen et al. 2005).
FOXC2 is a forkhead transcription factor, which is
involved in the speciWcation of the lymphatic capillary ver-
sus collecting lymphatic vessel phenotype. This factor is
highly expressed in the developing lymphatic vasculature
and in the luminal valves in adult lymphatic vessels (Dage-
nais et al. 2004; Petrova et al. 2004). Initial development of
the lymphatic vasculature proceeds normally in the absence
of FOXC2; however, later the patterning of the lymphatic
vasculature becomes abnormal. Collecting lymphatic ves-
sels in Foxc2¡/¡ mice fail to develop valves while the lym-
phatic capillaries acquire an excessive coverage by SMCs
and components of the basal lamina, and begin to express
some blood vascular endothelial cell markers such as
Endoglin and PDGF-B (Petrova et al. 2004). Mice hetero-
zygous for both Foxc2 and Vegfr3 display a phenotype very
similar to Foxc2¡/– mice, suggesting that FOXC2 and
VEGFR-3 act through a common genetic pathway to estab-
lish some of the distinct properties of the lymphatic vascu-
lature. The human disease lymphedema-distichiasis (LD),
an autosomal dominant disease, is caused by heterozygous-
loss-of-function mutations of Foxc2 (Fang et al. 2000).
Unlike in congenital lymphedema, the lymphatic vascula-
ture in LD is normal or hyperplastic, but there is lymph
backXow, presumably due to abnormal lymphatic valves,
defective patterning and the presence of ectopic SMCs
(Brice et al. 2002; Petrova et al. 2004). Interestingly, a
recent study showed that Foxc2 mutations are associated
with primary venous valve failure in both the superWcial
and deep veins in the lower limb. Thus, this gene appears to
be important for the normal development and maintenance
of both venous and lymphatic valves (Mellor et al. 2007).
Podoplanin, a small transmembrane mucin-like protein,
is highly expressed in lymphatic endothelial cells. In mice,
its expression starts around E11 and remains high both in
collecting lymphatic vessels and in lymphatic capillaries in
the adult (Breiteneder-GeleV et al. 1999; Schacht et al.
2003). Pdpn-deWcient mice die at birth due to abnormal
lung development and have defects in lymphatic but not
blood vessel formation and patterning, which result in
impaired lymphatic transport, dilation of lymphatic vessels,
and congenital lymphedema (Schacht et al. 2003). Podoplanin
is upregulated in the invasive front of many human carcino-
mas and promotes collective cell migration by Wlopodia
formation via the downregulation of the activities of small
Rho family GTPases (Wicki et al. 2006). In contrast to
the role in tumor cells, siRNA mediated knockdown of
Podoplanin in lung LECs prevented activation of RhoA
during capillary morphogenesis and impaired localization
of phosphorylated ezrin/radixin/moesin proteins to plasma
membrane (Navarro et al. 2008).
Other regulators of lymphatic vascular development
Spred-1 and Spred-2, two negative regulators for growth
factor- and cytokine-induced ERK activation, were
reported as mediators of the separation of lymphatic vessels
from the parental vein, and Spred-1/Spred-2 double-knock-
out phenotype resembles that of Syk- and Slp-76-deWcient
mice. Spred proteins were shown to regulate VEGF-C sig-
naling by suppressing VEGFR-3-mediated ERK and Akt
activation (Taniguchi et al. 2007). However, the phenotype
of Spred-1/Spred-2 knockout mice diVers from the one
observed in Vegfc knockout or Vegfr3 mutant Chy mice
(Karkkainen et al. 2004), therefore alternative explanations
should be also considered.
Adrenomedullin (AM), a vasodilatator and diuretic pep-
tide, is necessary for murine lymphatic vascular develop-
ment (Fritz-Six et al. 2008; Jin et al. 2008). Genetic loss of
AM or components of its receptor complex, calcitonin
receptor-like receptor and receptor activity-modifying pro-
tein 2 (RAMP2), leads to non-hemorrhagic edema and
embryonic lethality at midgestation (Fritz-Six et al. 2008).
The initial development of lymphatic vasculature was not
aVected; however, loss of AM signaling resulted in severely
hypoplastic jugular lymph sacs while the development of
retroperitoneal and skin lymphatic vessels was normal.
Administration of AM was also shown to improve second-
ary lymphedema in mouse tail lymphedema model, and to
promote lymphangiogenesis (Jin et al. 2008). Interestingly,
in contrast to Fritz-Six et al., another study of RAMP2 deW-
cient mice concluded that AM has blood vascular functions,
such as regulation of vascular stability and permeability,
and that embryos lacking AM signaling die due to leaky
and unstable blood vessels (Ichikawa-Shindo et al. 2008),
therefore further work may be necessary to reconcile these
results and to unravel details of AM signaling in the vascu-
lature during embryonic development.
Aspp1 (apoptosis stimulating protein of p53), an endo-
thelial-speciWc gene functioning in mouse embryogenesis,
was recently described as an important player in the lym-
phatic vessel assembly. Aspp1¡/¡ mice showed a disorga-
nized lymphatic plexus and impaired lymphatic drainage
function in embryonic skin, whereas the lymphatic drainage
defect was resolved in adults. Moreover, collecting lymphatic123
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These results indicate that Aspp1 is important for the initial
assembly of lymphatic endothelial cells but dispensable for
lymphatic remodeling (Hirashima et al. 2008). The lym-
phatic vascular function of Aspp1 is independent of p53,
and may be linked instead to C-terminal Src kinase (Csk),
given the fact the Drosophila homologue of Aspp1 acts as a
positive regulator of dCsk in the control of epithelial integ-
rity (Langton et al. 2007).
Recently, Sphingosine-1-phosphate (S1P), a potent bio-
active lipid that is implicated in a variety of biologic pro-
cesses such as inXammatory responses and angiogenesis,
was reported as a lymphangiogenic mediator (Yoon et al.
2008). S1P induces the migration and capillary-like tube
formation of lymphatic endothelial cells in vitro and lym-
phangiogenesis in vivo. Furthermore, the use of pertussis
toxin, intracellular Ca2+ chelator, and phospholipase C
(PLC) inhibitor eYciently blocks S1P-induced in vitro lym-
phangiogenesis and intracellular Ca2+ mobilization of
HLECs, suggesting that S1P promotes lymphangiogenesis
by stimulating S1P1/Gi/phospholipase C/Ca2+ signaling
pathways.
TGF- signaling negatively regulates lymphangiogene-
sis in inXammatory tissues as well as in certain tumor tis-
sues. In addition to inhibiting the proliferation and
migration of human dermal lymphatic microvascular endo-
thelial cells, TGF- decreases the expression of LEC-
related genes, including Prox1 and Lyve1, in these cells.
Moreover, TGFR-I inhibitor potentiates lymphangiogene-
sis in the presence of VEGF-C in vivo (Oka et al. 2008).
Finally, Emilin1, an elastic microWbril-associated pro-
tein, is expressed in lymphatic endothelial cells, and plays a
role in the regulation of lymphatic vessel patterning and
proliferation (Danussi et al. 2008). Emilin1¡/- mice have
hyperplastic and disorganised lymphatic vessels with
reduced number of anchoring Wlaments, and they also show
impaired lymphatic drainage function. These data highlight
the importance of interactions between LECs and surround-
ing ECM (Danussi et al. 2008).
Pathology of lymphatic vessels
The lymphatic vascular system is a dynamic structure that
responds to a changing environment and evolves during the
life of individual. In the adult, many pathological condi-
tions aVect the lymphatic vessels and they respond by
undergoing neo-lymphangiogenesis. Such events include
inXammation and immune responses, tumorigenesis and
after trauma, infections, surgery and radiation. Many of the
known regulators of developmental lymphangiogenesis
have also been implicated in neo-lymphangiogenesis and
pathological conditions.
Lymphedema
Congenital or acquired dysfunction of the lymphatic sys-
tem can result in the formation of lymphedema, due to the
stagnation of lymph and accumulation of tissue Xuid
because of an impairment of the capacity to remove Xuid
from the interstitium (Fig. 2a). This may be caused by
abnormal lymphatic vessel development or damaged lym-
phatic vessels. Lymphedema is a progressive disease char-
acterized by swelling of the aVected limb, accompanied by
Wbrosis, fatty degeneration of the connective tissue and
susceptibility to infections (reviewed by Rockson 2001).
The treatment of lymphedema is currently based on manual
lymphatic drainage by physiotherapy, compression gar-
ments, and occasionally surgery. Lymphedema is usually
divided into two main categories. Primary lymphedema is
a condition with no identiWable antecedent cause that can
be present at birth (congenital), at puberty (praecox) or,
more rarely, at adulthood (tarda). Secondary, acquired
lymphedema develops when the lymphatic vessels are
damaged by infection, for example as a result of parasitic
infection (Wliariasis), radiation therapy, or when lymph
nodes are surgically removed.
Milroy’s disease or primary congenital lymphedema
(Online Mendelian Inheritance in Man, OMIM, number
153100), becomes apparent at birth, aVects primarily the
legs and feet and is characterized by an absence or reduced
number of lymphatic vessels (Brice et al. 2005). This dis-
ease has been associated with missense mutations encoding
inactive tyrosine kinase VEGFR-3 proteins (Butler et al.
2007; Irrthum et al. 2000; Karkkainen et al. 2000). Muta-
tions in Vegfr3 were identiWed in mutant mouse strain Chy,
which has defective lymphatic vessels (Karkkainen et al.
2001). This model has been used to test VEGF-C gene ther-
apy, which promoted the formation of functional lymphatic
vessels in these mice. In the case of lymphedema-distichia-
sis (LD, OMIM 153400), mutations in the forkhead tran-
scription factor FOXC2 have been identiWed (Fang et al.
2000; Finegold et al. 2001). This disorder is characterized
by distichiasis (a double row of eyelashes) at birth and
bilateral lower limb lymphedema at puberty. LD is associ-
ated with abnormal lymph vessel patterning, agenesis of
lymphatic valves, and abnormal recruitment of SMCs (Petr-
ova et al. 2004). Generated Foxc2§ and Foxc2¡/¡ mice
constitute useful animal models for this disorder (Krieder-
man et al. 2003; Petrova et al. 2004). A recent study
reported renal disease and diabetes mellitus in combination
with LD caused by a Foxc2 mutation, reXecting the devel-
opmental role of FOXC2 in multiple tissues (Yildirim-
Toruner et al. 2004). Finally, mutations in the transcription
factor SOX18 were recently identiWed in recessive and
dominant forms of hypotrichosis–lymphedema–telangiec-
tasia (Irrthum et al. 2003).123
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probably the most common cause of lymphedema in indus-
trialized countries. The reported incidence of edema after
mastectomy, approximately 6–30% of operated patients, is
increased by radiotherapy, but its etiology and pathophysi-
ology are still not fully understood and appear to be multi-
factorial (reviewed by Rockson 2001). A recent study,
using a newly established axillary lymphadenectomy
mouse model, showed that collecting lymphatic vessels can
be regenerated and fused to lymph node transplants after
lymph node removal. Treatment with adenovirally deli-
vered VEGF-C or VEGF-D induces robust growth of the
lymphatic capillaries, which can mature and become func-
tional even without the presence of lymph nodes. Further-
more, VEGF-C therapy greatly improves the success of
lymph node survival; without VEGF-C the transplantation
leads to atrophy of lymph node structure. Combination of
VEGF-C therapy and lymph node transplantation thus pro-
vides a working model for treating individuals with a his-
tory of cancer (Tammela et al. 2007).
Worldwide, the main cause of lymphedema is Wlariasis,
in over 80 tropical and subtropical countries, with about
120 million people aVected (Wynd et al. 2007). This dis-
ease is caused by infection with the mosquito-borne para-
sites Wuchereria bancrofti and Brugia malayi, which live
and reproduce in the lymphatic system. This leads to a mas-
sive damage of lymphatic vessels with a complete and per-
manent disruption of lymphatic transport, resulting in
chronic lymphedema of the legs and genitals (reviewed by
Melrose 2002). Current drugs (diethylcarbamazine or iver-
mectin, usually given with albendazole) eVectively killed
the microWlariae (larval oVspring of the parasite), but their
eVect on the macroWlariae (adult worms) was incomplete.
Doxycycline was suggested as a novel strategy against
Fig. 2 Lymphatic vasculature in disease. a Malformation of lymphat-
ic capillaries, damage to collecting lymphatic vessels and lack or
insuYcient function of lymphatic valves can lead to lymphedema.
Abnormal coverage by smooth muscle cells (SMC), observed in some
lymphedema patients, may also compromise the function of lymphatic
capillaries and leads to insuYcient lymph drainage. b InXammatory
cells produce proinXammatory cytokines and lymphangiogenic factors
that stimulate lymphatic vessel growth. Lymphatic endotheial cells
produce CCL21, which further attracts CCR7+ lymphocytes and den-
dritic cells. VEGF-A is prominently expressed by follicular B cells and
is a potential mediator of the increase in lymphatic vessels and DC
migration in inXamed lymph nodes. c Tumor and tumor-associated
macrophages secrete factors, such as VEGF-C and VEGF-D, which
can induce lymphatic vessel growth in the periphery of and/or inside
the tumor as well as in the draining sentinel lymph nodes. The lymphat-
ic endothelial cells may also actively attract some tumor cells through
the secretion of chemokines, such as CCL21. Tumor-associated and
lymph node lymphangiogenesis can lead to enhanced metastasis to
sentinel lymph nodes and beyond to distant organs123
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intracellular bacterial symbiont of Wlarial parasites, and
kills most adult worms (Hoerauf et al. 2003; Stolk et al. 2005).
InXammation
InXammation and immune system dysfunction are inti-
mately associated with increased lymphangiogenesis.
VEGF-C is upregulated in response to proinXammatory
cytokines, presumably through NF-B-mediated promoter
activation, suggesting a role for the regulation of lymphatic
vessel growth during inXammation (Ristimaki et al. 1998).
Interestingly, NF-B is also constitutively active in at least
some lymphatic vessels (Saban et al. 2004). Lymphatic ves-
sels actively regulate inXammatory responses by transport-
ing leukocytes from the site of inXammation to secondary
lymphoid organs (Fig. 2b). Upon exposure to an inXamma-
tory stimulus and recognition of pathogen-associated
molecular patterns, dendritic cells (DC) capture antigens in
peripheral tissues and migrate through aVerent lymphatic
vessels into lymph nodes. After their maturation, DC
express higher levels of the speciWc lymphoid chemokine
receptor CCR7 (Sallusto et al. 1998) that promotes their
migration into lymph node, attracted by the ligand of
CCR7, the chemokine CCL21 (or SLC, Secondary Lym-
phoid tissue Chemokine) produced by the lymphatic vascu-
lar endothelium of aVerent vessels (Ohl et al. 2004; Saeki
et al. 1999; Sallusto et al. 1998). Antigenic peptide-loaded
DC are transported by lymph to the subcapsular sinus and
enter the paracortex zone where they aggregate preferen-
tially around high endothelial venules (HEV), on the entry
route of T cells into the paracortex, and thus may foster the
presentation of major histocompatibility complex (MHC)-
peptide complexes to passing T cells and optimize initial T
cell activation (BajenoV et al. 2003). In addition, native
antigen-loaded DC could encounter B cells that enter the
lymph node by HEV and activate them (Qi et al. 2006).
Other cell types are also transported by aVerent vessels,
such as T and B lymphocytes and macrophages (Mackay
et al. 1988). Indeed DC, T, and B cells leave peripheral tis-
sues and migrate towards lymph nodes owing to their
expression of chemokine receptor CCR7 (Bromley et al.
2005; Debes et al. 2005). Additional mechanisms that could
also control this aZux of lymphocytes include interactions
of lymphocytes with adhesion molecules expressed by lym-
phatic endothelium as CLEVER-1 (Common Lymphatic
Endothelial and Vascular Receptor-1) (Salmi et al. 2004)
and Mannose receptor 1 (Irjala et al. 2001). Finally, naive T
and B cells, which have failed to Wnd their speciWc antigen,
or activated T cells, will go through medullary cords before
reaching eVerent vessels, and then return to bloodstream.
Exit of lymphocytes depends on the expression of a G pro-
tein coupled receptor, Sphingosine-1-phosphate 1 (S1P1)
by lymphatic endothelial cells and its ligand S1P expressed
by lymphocytes (Mandala et al. 2002; Matloubian et al.
2004). Immunisation leads to enhanced lymph node lym-
phangiogenesis, an event that in turn leads to improved DC
mobilisation. Of particular note, lymphangiogenesis
occurred not only at the infection site and the draining
lymph node, but also in uninvolved peripheral tissue that
drains to the same lymph node. VEGF-A, ligand of
VEGFR-2, which is highly expressed by follicular B cells,
is a possible mediator of the increase lymphangiogenesis
and DC migration (Angeli et al. 2006).
Macrophages are suggested to have a dual role in inXam-
mation-induced lymphangiogenesis (Kerjaschki 2005).
Macrophages recruited into the inXammation site can trans-
form from naive monocytes into VEGF-C/D-producing
cells, which can stimulate the growth of existing LECs
(Schoppmann et al. 2002). They might also contribute to
lymphangiogenesis by trans-diVerentiating to lymphatic
endothelial cells, which incorporate into the lymphatic
endothelium (Maruyama et al. 2005). Furthermore, human
kidney transplant rejection is frequently accompanied by
lymphangiogenesis, and these lymph vessels produced
CCL21, which further attracted CCR7+ lymphocytes and
DC, and might actively promote the inXammatory process
(Kerjaschki et al. 2004). In addition, other inXammatory
diseases seem to be associated with lymphatic activation
and dysfunction. For example, lymphatic hyperplasia is
observed in UVB-irradiation-induced skin inXammation, in
a mouse model of chronic skin inXammation resembling
psoriasis, and in human psoriatic skin lesions (Kajiya et al.
2006; Kunstfeld et al. 2004). In chronic airway inXamma-
tion induced by Mycoplasma pulmonis, a massive lymphan-
giogenesis is induced by VEGF-C/-D-producing
inXammatory cells, and its blocking resulted in bronchial
lymphedema, thus demonstrating the importance of lym-
phangiogenesis for compensation of vascular leakage dur-
ing the inXammation (Baluk et al. 2005). Finally, the role of
VEGF-C/D–VEGFR-3 signaling in inXammatory lymphan-
giogenesis is also suggested by overexpression of VEGF-C
in the joint synovium of rheumatoid arthritis patients
(Paavonen et al. 2002). These studies underline the close
relationship between inXammation, the immune response
and the adaptability of a mature lymphatic network.
Tumor lymphangiogenesis
Tumor metastasis to regional lymph nodes often represents
the Wrst step of tumor dissemination and serves as a major
prognostic indicator for the progression of human cancers.
A variety of mechanisms may contribute to the dissemina-
tion of primary malignant cancer cells: local tissue inva-
sion, systemic metastasis via tumor-associated blood
vessels to distant organs, and lymphatic metastasis via123
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nel) lymph node, distal lymph nodes, and from there to dis-
tal organs. The latter pathway constitutes the most common
pathway of initial metastasis for many types of solid human
tumors (reviewed by Stacker et al. 2002b). The extent of
lymph node metastasis is a major determinant for the stag-
ing and the prognosis of most human malignancies and
often guides therapeutic decisions. Despite this, the molec-
ular mechanisms of lymphatic metastasis are not com-
pletely understood.
Dissemination of tumor cells from the primary sites to
the lymphatic system is accomplished either by invasion
into pre-existing lymphatic vessels in the surrounding tis-
sues or by invasion into intratumoral lymphatic networks
(Achen et al. 2005; Alitalo et al. 2004; Cao et al. 2004; Cao
2005; Karpanen et al. 2001; Mandriota et al. 2001; Skobe
et al. 2001; Stacker et al. 2001a). In some cases of human
cancers the presence of lymphatic vessels inside the tumor
was reported to correlate positively with lymph node metas-
tasis and poor prognosis (Beasley et al. 2002; Kyzas et al.
2005). However, the issue whether intratumoral lymphatic
vessels are important for tumor spread is controversial;
indeed, intratumoral lymphatic vessels might be poorly
functional and not required for lymphatic metastasis (Padera
et al. 2002; Wong et al. 2005). In contrast to intratumoral
vessels, peritumoral lymphatic vessels certainly are func-
tional and have a drainage function (He et al. 2002, 2004;
Padera et al. 2002). In addition, tumor cells produce lymph-
angiogenic factors that could dilate the pre-existing lym-
phatic vessels surrounding the tumor tissue. Some of these
factors are able to facilitate the transmigration of tumor cells
through the lymphatic endothelium (Alitalo et al. 2004).
Tumor cells and tumor-associated macrophages can
express lymphangiogenic factors VEGF-C and VEGF-D,
thus they could play a role in peritumoral lymphangiogene-
sis and subsequent dissemination in human cancer
(Schoppmann et al. 2002) (Fig. 2c). Studies in animal
tumor models have provided direct experimental evidence
that increased levels of VEGF-C or VEGF-D promote
active tumor lymphangiogenesis and lymphatic tumor
spread to regional lymph nodes (Karpanen et al. 2001;
Mandriota et al. 2001; Skobe et al. 2001; Stacker et al.
2001b). These eVects are suppressed by speciWc inhibition
of the VEGFR-3 pathway—using either blocking VEGFR-
3 antibody, VEGF-C/D trap (VEGFR-3 extracellular
domain fused with immunoglobulin Fc portion) or VEGF-
C targeting siRNA—that prevents cancer metastasis to
lymph nodes and beyond (e.g. (He et al. 2002; Karpanen
et al. 2001; Lin et al. 2005; Roberts et al. 2006), underlin-
ing the direct link between VEGF-C or VEGF-D expres-
sion and metastasis. Moreover, a large number of
clinicopathological studies of human cancers have shown a
direct correlation between expression of VEGF-C or
VEGF-D by tumor cells and lymphatic invasion, lymph
node and distant metastasis, and poor patient survival, but
not necessarily with the density of tumor-associated lym-
phatic vessels (Achen et al. 2005; Pepper et al. 2003;
Stacker et al. 2002a; Tobler and Detmar 2006). Combina-
tion of siRNA therapy targeting both VEGF-C and VEGF-
A inhibits both lymph node and lung metastasis in a mouse
immunocompetent mammary cancer model, rendering this
combined therapy more beneWcial than either alone
(Shibata et al. 2008).
VEGF-C stimulates the growth of new tumor-associated
lymphatic vessels, and in this process nearby LECs send
Wlopodia toward VEGF-C producing tumor cells, and then
form tumor-directed vessel sprouts, where the vessel lumen
opens up and allows facilitated access of tumor cells to the
lumen (He et al. 2005). The lymphatic endothelium may
also actively participate in metastasis formation by secret-
ing chemokines such as CCL21, whose receptor is
expressed on some malignant cells (Shields et al. 2006;
Zlotnik 2004). Moreover, intraluminal VEGF-C also pro-
motes the dilation of collecting lymphatic vessels through
the process of endothelial proliferation in the vessel wall,
and further enhances the delivery of tumor cells to sentinel
lymph nodes, probably by increasing the lymph Xow rate
(He et al. 2005; Hoshida et al. 2006).
Overexpression of VEGF-C or VEGF-A under the
control of keratinocyte-speciWc promoter can induce active
proliferation of tumor-associated lymphatic vessels in a
multi-step skin carcinogenesis model, leading to enhanced
tumor metastasis to the sentinel and distant lymph nodes
(Hirakawa et al. 2005, 2007). This eVect is preceded by lym-
phangiogenesis in sentinel lymph nodes, which suggests that
primary tumors can prepare their future metastatic site in
advance of their arrival, partly by producing lymphangio-
genic factors. Induction of lymph node lymphangiogenesis
and increased lymph Xow through tumor-draining lymph
nodes, prior to tumor cell arrival, was suggested to be B cell-
dependent (Harrell et al. 2007). In addition, not only can
cancer cells ‘prepare the ground’ for metastasis, but also
stromal cells might serve as important mediators for tumor-
induced lymphangiogenesis. A recent study, using a condi-
tional transgenic mouse model of breast cancer, showed that
hyaluronan-rich tumor microenvironment plays an impor-
tant role in promoting tumor lymphangiogenesis, thus dem-
onstrating the importance of the tumor stromal cells and
extracellular matrix in educating malignant cells to secrete
speciWc lymphangiogenic factors (Koyama et al. 2008).
Concluding remarks
In recent years, novel molecules regulating the development,
diVerentiation, morphogenesis and functional expression123
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identiWed, resulting in marked advances in the Weld of lym-
phangiogenesis. Progress in technical tools such as sophis-
ticated animal models, better imaging techniques that allow
work at cellular or subcellular resolution and in live ani-
mals during dynamic studies and high throughput genomic
or proteomic screens, have made vascular morphogenesis
much more accessible to research. However, many ques-
tions concerning some fundamental processes of physiolog-
ical and pathological lymphangiogenesis are yet remain
unresolved.
Early steps of lymphatic endothelial cell commitment
are not yet completely understood, and the mechanisms of
lymphatic vascular remodeling and maturation are only
beginning to be elucidated. It will be important to clarify
the importance of mesenchymal lymphangioblasts as a sec-
ondary source of LECs, other than the venous endothelium.
Furthermore, signals that induce PROX1 expression in a
restricted subpopulation of endothelial cells and direct
PROX1 target genes that act as its eVectors in lymphatic
endothelium remain to be identiWed. Lymphangiogenesis
bears a close resemblance to angiogenesis, yet it appears
that lymphatic vasculature uses distinct molecular mecha-
nisms. It will be important to understand the basis for such
diVerences and identify signaling pathways that control
diVerent stages of lymphatic vascular development. Further
studies are needed to pinpoint the mechanisms that keep the
emerging lymphatic vessels separate from blood vessels.
This process appears to be complex and it is likely that
includes other factors in addition to Syk/Slp76. Further-
more, the lymphatic vascular tree is composed of a system
of lymphatic vessels of diVerent size and morphology; it
would be interesting to study the phenotypic and genotypic
diVerences of the LECs that comprise these vessels, and to
characterize endothelial, molecular, and phenotypic vari-
ability through the lymphatic vasculature system.
Answers to these questions will help to provide a com-
prehensive picture of lymphatic vascular development, and
will contribute to our understanding of the mechanisms
involved in lymphatic vascular dysfunction in lymphe-
dema, inXammation, and cancer. In the case of lymphe-
dema-distichiasis, it is necessary to extend the study of the
role of FOXC2, and to identify direct FOXC2 target genes
to enhance our understanding of the morphogenesis and
diVerentiation of intraluminal valves.
The involvement of lymphatic vessels in inXammation
should be explored in several contexts, and the impact of
inXammation on the phenotype and function of lymphatic
vessels needs to be investigated. In this way, a clear vision
of physiological and ectopic lymph node neogenesis should
provide information about the link between lymphatic ves-
sels and lymph nodes. Finally, it is of great importance to
have a better understanding of the importance of tumor-
associated lymphangiogenesis in the spread of cancer to
distant organs. The elucidation of the molecular mecha-
nisms of lymphatic metastasis represents another challenge
that will be instrumental in our understanding of how to
control the spread of cancers in patients. It has become evi-
dent over the last decade that VEGFR-3 and its ligands
VEGF-C and VEGF-D are critical targets for new drug
development. The question now concerns the potential
eYcacy of targeting such lymphangiogenic growth factors
in the management of cancer. In addition, the involvement
of tumor microenvironment in neo-lymphangiogenesis has
to be addressed, and with this the identiWcation of stromal
and immune determinants. That also implies studying the
interactions between stromal cells and LECs, which could
promote further development of lymphatic vessels. Immune
cells have been shown to participate in tumor progression,
and tumor immunomodulation could also form a part along
with lymphangiogenic growth factor signaling, of processes
that promote metastasis through the lymphatic system. The
challenge for future studies is to identify new molecular
and cellular players and increase our understanding of the
basic biology of lymphatic development, which will con-
tribute to designing novel therapeutic strategies for treat-
ment of diVerent lymphatic disorders.
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